Claims
- 1. A pharmaceutical preparation for treating colon cancer comprising a pharmaceutically acceptable carrier and a tumor-inhibiting amount of an azamitosene.
- 2. A preparation according to claim 1 in which said azamitosenes have the structural formula: ##STR12## wherein: R is ##STR13##
- 3. A pharmaceutical preparation according to claim 1 in which the azamitosene is selected from the group consisting of 6-(N-Aziridinyl)-7-methyl-2, 3-dihydro-1H-pyrrolo benzimidazole-5,8-dione-3-acetate, and 6-(N-Aziridinyl)-7-methyl-2, 3-dihydro-1H-pyrrolo benzimidazole-5, 8-dione-3-carbamate.
- 4. A pharmaceutical preparation for treating a neoplastic disease selected from the group consisting of colon cancer, ovarian cancer, and myeloma comprising a pharmaceutically acceptably carrier and a tumor-inhibiting amount of a compound selected from the group consisting azamitosenes having the structural formula: ##STR14## wherein Z is selected from the group consisting of ##STR15##
- 5. A method of treating a host afflicted with a neoplastic disease selected from the group consisting of colon cancer, ovarian cancer, and myeloma, comprising administering to said host an effective amount of a compound selected from the group consisting of: ##STR16## wherein Z is selected from the group consisting of ##STR17##
- 6. A method according to claim 5 in which said substance is administered intravenously, at a dosage level of from 0.1 up to about 20 mg per kilogram of host body weight.
- 7. A method according to claim 5 in which said substance is administered intravenously, at a dosage level of from 1 up to about 50 mg per kilogram of host body weight.
- 8. A method according to claim 5 in which said substance is administered orally, at a dosage level of from 5 up to about 100 mg per kilogram of host body weight.
- 9. A method according to claim 5 in which said effective amount comprises from about 1 up to about 4 g per kilogram of host body weight.
Parent Case Info
This is a continuation of application Ser. No. 07/502,334 filed Mar. 30, 1990 and now abandoned.
Government Interests
This invention was made with government support under grant No. 2 RO1CA 36876 awarded by the National Institute of Health. The U.S. government has certain rights in this invention.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5015742 |
Skibo |
May 1991 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0449649 |
Oct 1991 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Islam et al "Synthesis and Physical Studies of Azamitosene and Iminoazamitosene Reductive Alkylating Agents" J. Org. Chem. 1990, 55, 3195-3205. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
502334 |
Mar 1990 |
|